163 related articles for article (PubMed ID: 34996331)
1. TransCon human growth hormone for children with growth hormone deficiency: a technology evaluation.
Dos Santos JBR; Da Silva MRR
Expert Opin Drug Deliv; 2022 Jan; 19(1):1-7. PubMed ID: 34996331
[TBL] [Abstract][Full Text] [Related]
2. Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial.
Thornton PS; Maniatis AK; Aghajanova E; Chertok E; Vlachopapadopoulou E; Lin Z; Song W; Christoffersen ED; Breinholt VM; Kovalenko T; Giorgadze E; Korpal-Szczyrska M; Hofman PL; Karpf DB; Shu AD; Beckert M
J Clin Endocrinol Metab; 2021 Oct; 106(11):3184-3195. PubMed ID: 34272849
[TBL] [Abstract][Full Text] [Related]
3. Switching to Weekly Lonapegsomatropin from Daily Somatropin in Children with Growth Hormone Deficiency: The fliGHt Trial.
Maniatis AK; Nadgir U; Saenger P; Reifschneider KL; Abuzzahab J; Deeb L; Fox LA; Woods KA; Song W; Mao M; Chessler SD; Komirenko AS; Shu AD; Casella SJ; Thornton PS
Horm Res Paediatr; 2022; 95(3):233-243. PubMed ID: 35263755
[TBL] [Abstract][Full Text] [Related]
4. Lonapegsomatropin: Pediatric First Approval.
Lamb YN
Paediatr Drugs; 2022 Jan; 24(1):83-90. PubMed ID: 34709591
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Lonapegsomatropin in Children With Growth Hormone Deficiency: enliGHten Trial 2-Year Results.
Maniatis AK; Casella SJ; Nadgir UM; Hofman PL; Saenger P; Chertock ED; Aghajanova EM; Korpal-Szczyrska M; Vlachopapadopoulou E; Malievskiy O; Chaychenko T; Cappa M; Song W; Mao M; Mygind PH; Smith AR; Chessler SD; Komirenko AS; Beckert M; Shu AD; Thornton PS
J Clin Endocrinol Metab; 2022 Jun; 107(7):e2680-e2689. PubMed ID: 35428884
[TBL] [Abstract][Full Text] [Related]
6. Average IGF-1 Prediction for Once-Weekly Lonapegsomatropin in Children With Growth Hormone Deficiency.
Lin Z; Shu AD; Bach M; Miller BS; Rogol AD
J Endocr Soc; 2022 Jan; 6(1):bvab168. PubMed ID: 34913019
[TBL] [Abstract][Full Text] [Related]
7. Spotlight on Lonapegsomatropin Once-Weekly Injection and Its Potential in the Treatment of Growth Hormone Deficiency in Pediatric Patients.
Miller BS; Yuen KCJ
Drug Des Devel Ther; 2022; 16():2055-2066. PubMed ID: 35791404
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life in pre-pubertal children with pediatric growth hormone deficiency: 12-month results from a phase 3 clinical trial of once-weekly somatrogon versus once-daily somatropin.
Loftus J; Quitmann J; Valluri SR
Curr Med Res Opin; 2024 Feb; 40(2):175-184. PubMed ID: 38053515
[TBL] [Abstract][Full Text] [Related]
9. Weekly Growth Hormone (Lonapegsomatropin) Causes Severe Transient Hyperglycemia in a Child with Obesity.
Alkhatib EH; Dauber A; Estrada DE; Majidi S
Horm Res Paediatr; 2023; 96(5):542-546. PubMed ID: 37015214
[TBL] [Abstract][Full Text] [Related]
10. Association of Daily Growth Hormone Injection Adherence and Height Among Children With Growth Hormone Deficiency.
Loftus J; Miller BS; Parzynski CS; Alvir J; Chen Y; Jhingran P; Gupta A; DeKoven M; Divino V; Tse J; He J; Wajnrajch M
Endocr Pract; 2022 Jun; 28(6):565-571. PubMed ID: 35263660
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety, quality of life, adherence and cost-effectiveness of long-acting growth hormone replacement therapy compared to daily growth hormone in children with growth hormone deficiency: A systematic review and meta-analysis.
Mameli C; Orso M; Calcaterra V; Wasniewska MG; Aversa T; Granato S; Bruschini P; Guadagni L; d'Angela D; Spandonaro F; Polistena B; Zuccotti G
Pharmacol Res; 2023 Jul; 193():106805. PubMed ID: 37236413
[TBL] [Abstract][Full Text] [Related]
12. Lonapegsomatropin (Skytrofa) for growth hormone deficiency.
Med Lett Drugs Ther; 2022 Feb; 64(1643):20-22. PubMed ID: 35134048
[No Abstract] [Full Text] [Related]
13. Cost-effectiveness and cost-utility analysis of somatrogon once-weekly injections vs. daily growth hormone injection for treating paediatric growth hormone deficiency in Ireland.
Rivolo S; Loftus J; Peter B; Fahey M; Kongnakorn T
J Med Econ; 2023; 26(1):963-972. PubMed ID: 37527156
[TBL] [Abstract][Full Text] [Related]
14. A Randomized Phase 2 Study of Long-Acting TransCon GH vs Daily GH in Childhood GH Deficiency.
Chatelain P; Malievskiy O; Radziuk K; Senatorova G; Abdou MO; Vlachopapadopoulou E; Skorodok Y; Peterkova V; Leff JA; Beckert M;
J Clin Endocrinol Metab; 2017 May; 102(5):1673-1682. PubMed ID: 28201598
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of a new ready-to-use recombinant human growth hormone solution.
Romer T; Peter F; Saenger P; Starzyk J; Koehler B; Korman E; Walczak M; Wasik R; Ginalska-Malinowska M; Solyom E; Berghout A
J Endocrinol Invest; 2007; 30(7):578-89. PubMed ID: 17848841
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of somatropin for the treatment of short children born small for gestational age.
Christensen T; Buckland A; Bentley A; Djurhuus C; Baker-Searle R
Clin Ther; 2010 Jun; 32(6):1068-82. PubMed ID: 20637961
[TBL] [Abstract][Full Text] [Related]
17. Developments in the Management of Growth Hormone Deficiency: Clinical Utility of Somapacitan.
Miller BS; Blair J; Horikawa R; Linglart A; Yuen KCJ
Drug Des Devel Ther; 2024; 18():291-306. PubMed ID: 38333899
[TBL] [Abstract][Full Text] [Related]
18. What do we do now that the long-acting growth hormone is here?
Miller BS
Front Endocrinol (Lausanne); 2022; 13():980979. PubMed ID: 36072938
[TBL] [Abstract][Full Text] [Related]
19. Persistence with daily growth hormone among children and adolescents with growth hormone deficiency in the UK.
Loftus J; Wogen J; Oliveri D; Benjumea D; Jhingran P; Chen Y; Alvir J; Rivero-Sanz E; Kowalik JC; Wajnrajch MP
Front Endocrinol (Lausanne); 2022; 13():1014743. PubMed ID: 36407317
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
